Healio news story
Studies published in a medical journal and presented at a conference showed that tecovirimat did not increase clinical resolution of mpox and may contribute to antiviral resistance for people with HIV being treated for the disease.
Data shared at CROI 2026 provided additional insights, including evidence of the emergence of antiviral resistance emergence.
Read the full news story here.
View all Healio reports from CROI 2026
SEE ALSO:
Source : Healio
Related HIV and Co-Infections News
-
ECDC launches new monthly mpox surveillance report as transmission continues in Europe
-
NDTV: Mpox can infect and replicate in the brain, NIH researchers say in fatal HIV case
-
[Press release] University of Barcelona: People with HIV did not show more severe clinical symptoms during the 2022 mpox outbreak in Spain
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.